Pharvaris N.V. (PHVS)

$18.36 +0.91 (5.21%)
Market Cap 555.61M
Revenue (ttm) 0.00
Net Income (ttm) -109.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 25,900
Avg Vol 70,830
Day's Range N/A - N/A
Shares Out 31.84M
Stochastic %K 72%
Beta -3.06
Analysts Strong Sell
Price Target $32.83

Latest News on PHVS

Pharvaris Outlines 2025 Strategic Priorities

Jan 13, 2025, 6:50 AM EST - 4 days ago

Pharvaris Outlines 2025 Strategic Priorities

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Nov 13, 2024, 4:10 PM EST - 2 months ago

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

Nov 12, 2024, 6:50 AM EST - 2 months ago

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Oct 16, 2024, 6:50 AM EDT - 3 months ago

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Pharvaris to Host Virtual Investor Event on October 23, 2024

Oct 15, 2024, 6:50 AM EDT - 3 months ago

Pharvaris to Host Virtual Investor Event on October 23, 2024

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

Oct 3, 2024, 6:50 AM EDT - 3 months ago

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

Sep 5, 2024, 6:50 AM EDT - 4 months ago

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

Sep 5, 2024, 6:49 AM EDT - 4 months ago

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

Pharvaris Presents Data at the Bradykinin Symposium 2024

Sep 5, 2024, 6:48 AM EDT - 4 months ago

Pharvaris Presents Data at the Bradykinin Symposium 2024

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

Aug 28, 2024, 6:50 AM EDT - 5 months ago

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 6:50 AM EDT - 5 months ago

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

Pharvaris Announces Annual Meeting of Shareholders

Jun 11, 2024, 6:50 AM EDT - 7 months ago

Pharvaris Announces Annual Meeting of Shareholders

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Jun 4, 2024, 6:50 AM EDT - 8 months ago

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

May 13, 2024, 6:50 AM EDT - 8 months ago

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 4:10 PM EDT - 9 months ago

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Apr 10, 2024, 4:10 PM EDT - 10 months ago

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Apr 10, 2024, 4:08 PM EDT - 10 months ago

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Apr 4, 2024, 6:50 AM EDT - 10 months ago

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

Mar 18, 2024, 6:50 AM EDT - 10 months ago

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

Mar 6, 2024, 6:50 AM EST - 11 months ago

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

Mar 5, 2024, 6:50 AM EST - 11 months ago

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

Feb 22, 2024, 6:50 AM EST - 11 months ago

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

Pharvaris Announces Extraordinary Meeting of Shareholders

Feb 16, 2024, 6:50 AM EST - 1 year ago

Pharvaris Announces Extraordinary Meeting of Shareholders

Pharvaris to Present at the WSAAI Annual Meeting 2024

Jan 26, 2024, 6:50 AM EST - 1 year ago

Pharvaris to Present at the WSAAI Annual Meeting 2024

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Jan 22, 2024, 6:50 AM EST - 1 year ago

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

Jan 5, 2024, 6:50 AM EST - 1 year ago

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

Dec 8, 2023, 6:00 PM EST - 1 year ago

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

Pharvaris shares surge as treatment for severe swelling meets clinical trial goal

Dec 6, 2023, 8:12 AM EST - 1 year ago

Pharvaris shares surge as treatment for severe swelling meets clinical trial goal

Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants

Dec 6, 2023, 7:02 AM EST - 1 year ago

Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants

Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Dec 6, 2023, 6:50 AM EST - 1 year ago

Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Pharvaris to Present at the GA²LEN UCARE Conference 2023

Nov 30, 2023, 6:50 AM EST - 1 year ago

Pharvaris to Present at the GA²LEN UCARE Conference 2023

Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

Nov 15, 2023, 6:50 AM EST - 1 year ago

Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

Nov 9, 2023, 11:00 AM EST - 1 year ago

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 2, 2023, 6:50 AM EDT - 1 year ago

Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update

Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting

Oct 30, 2023, 6:50 AM EDT - 1 year ago

Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting

Pharvaris To Present at the APAAACI 2023 International Conference

Oct 13, 2023, 6:50 AM EDT - 1 year ago

Pharvaris To Present at the APAAACI 2023 International Conference

Pharvaris To Present at the CIIC Fall 2023 Conference

Oct 4, 2023, 7:34 AM EDT - 1 year ago

Pharvaris To Present at the CIIC Fall 2023 Conference

Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference

Sep 19, 2023, 6:50 AM EDT - 1 year ago

Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference

Pharvaris To Present at the 18th German Allergy Congress

Sep 6, 2023, 6:51 AM EDT - 1 year ago

Pharvaris To Present at the 18th German Allergy Congress

Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 6, 2023, 6:50 AM EDT - 1 year ago

Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Pharvaris To Present at the 2023 HAEi Regional Conference EMEA

Aug 23, 2023, 6:50 AM EDT - 1 year ago

Pharvaris To Present at the 2023 HAEi Regional Conference EMEA

Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 7, 2023, 6:50 AM EDT - 1 year ago

Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update

Pharvaris: FDA Lifts Clinical Hold, Progresses HAE Drug Development

Jul 27, 2023, 3:31 AM EDT - 1 year ago

Pharvaris: FDA Lifts Clinical Hold, Progresses HAE Drug Development

Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit

Jul 21, 2023, 10:20 AM EDT - 1 year ago

Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

Jun 26, 2023, 6:50 AM EDT - 1 year ago

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

Pharvaris Announces $70 Million Private Placement Financing

Jun 20, 2023, 6:50 AM EDT - 1 year ago

Pharvaris Announces $70 Million Private Placement Financing

Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

Jun 10, 2023, 6:01 PM EDT - 1 year ago

Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update

May 8, 2023, 6:50 AM EDT - 1 year ago

Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update

Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop

May 6, 2023, 1:00 PM EDT - 1 year ago

Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop

Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Apr 5, 2023, 6:51 AM EDT - 1 year ago

Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update